No specific molecular profile (NSMP) endometrial cancer
NSMP is the label an endometrial cancer gets when the three positive tests are all negative: no POLE mutation, intact mismatch repair and normal p53. It is the largest group, mostly hormone-driven and low grade, and it is treated by stage, grade and oestrogen receptor rather than by a molecular marker.
Overview
What is measured: a diagnosis by exclusion within the ProMisE and WHO 2020 classification. How: POLE exonuclease domain sequencing negative, mismatch repair immunohistochemistry (MLH1, PMS2, MSH2, MSH6) intact, p53 immunohistochemistry wild-type pattern. About half of endometrial carcinomas fall here, with an intermediate and heterogeneous outcome, so the group is refined by oestrogen receptor expression (ER-negative NSMP behaves like p53-abnormal disease), grade, L1CAM expression, lymphovascular space invasion, depth of myometrial invasion and CTNNB1 exon 3 mutation (higher recurrence in otherwise low-grade tumours). PTEN, PIK3CA and ARID1A mutations are frequent. What a result changes: adjuvant treatment follows the ESGO/ESTRO/ESP molecular risk groups (vaginal brachytherapy for intermediate risk, chemoradiation for high risk); advanced ER-positive NSMP disease is a candidate for endocrine therapy (progestins, aromatase inhibitors, with CDK4/6 inhibitors in trials); the RAINBO NSMP-ORANGE trial tests endocrine therapy in place of chemotherapy after radiotherapy. Where it matters: the NSMP endometrial page.
Similar pages
not linked directly; found by shared links- IdeaMolecular-class-directed adjuvant therapy in endometrial cancer
Shares Endometrial cancer molecular classes (POLEmut, MMRd, p53abn, NSMP), Endometrial cancer with no specific molecular profile, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR).
- TermPerineural invasion (PNI)
Shares Lymphovascular invasion (LVI), Depth of invasion (DOI).
- TermMLH1 promoter methylation (sporadic versus Lynch mismatch repair loss)
Shares Endometrial cancer with no specific molecular profile, Immunohistochemistry (IHC), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR).
- TreatmentVENTANA MMR RxDx Panel
Shares Endometrial cancer molecular classes (POLEmut, MMRd, p53abn, NSMP), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR).
- TermHER2-positive (IHC 3+ or ISH-amplified)
Shares Hormone receptor status (ER / PR), Immunohistochemistry (IHC).
- TermMicrosatellite-stable (MSS) / mismatch-repair proficient (pMMR)
Shares Endometrial cancer with no specific molecular profile, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR).
- TermMedulloblastoma molecular groups (WNT, SHH, group 3, group 4)
Shares TP53-mutated (p53-abnormal), Immunohistochemistry (IHC).
- TrialNRG-GY018 / KEYNOTE-868
Shares Endometrial cancer with no specific molecular profile, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR).